Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options

Rhea-AI Filing Summary

Aktis Oncology director Glenn Gormley received a grant of 37,866 stock options to buy common stock at an exercise price of $18.09 per share. The options expire on April 15, 2036. According to the vesting terms, one-third vests on April 15, 2027 and the remaining shares vest in equal annual installments thereafter, subject to his continuous service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gormley Glenn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	37,866	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 37,866 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 37,866 options Exercise price: $18.09 per share Post-transaction derivative holdings: 37,866 options +2 more

5 metrics

Stock options granted 37,866 options Grant to director Glenn Gormley reported on Form 4

Exercise price $18.09 per share Strike price for newly granted stock options

Post-transaction derivative holdings 37,866 options Total options held directly after grant

Option expiration date April 15, 2036 Final expiration for this option award

Initial vesting date April 15, 2027 One-third of options vest on this date

Key Terms

Stock Option (Right to Buy), Common Stock, vesting, exercise price

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)" for this grant"

Common Stock financial

"Each option is exercisable into shares of the company’s Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"One-third of the option shall vest in 2027 and the rest in equal annual installments thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"The options have an exercise price of $18.09 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gormley Glenn

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.09	04/15/2026		A		37,866		(1)	04/15/2036	Common Stock	37,866	$0.00	37,866	D

Explanation of Responses:

1. 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

	/s/ Ahnie Mondolfi, as Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aktis Oncology (AKTS) report for Glenn Gormley?

Aktis Oncology reported a grant of 37,866 stock options to director Glenn Gormley. These options allow him to buy common shares at $18.09 per share, providing equity-based compensation that aligns his interests with long-term shareholder value.

What is the exercise price of Glenn Gormley’s Aktis Oncology (AKTS) stock options?

The stock options granted to Glenn Gormley have an exercise price of $18.09 per share. This means he can purchase Aktis Oncology common stock at $18.09 once the options vest and remain outstanding, subject to the specified vesting schedule and expiration date.

How many Aktis Oncology (AKTS) options does Glenn Gormley hold after this Form 4?

After the reported grant, Glenn Gormley holds 37,866 stock options directly. Each option is exercisable for one share of Aktis Oncology common stock, contingent on vesting conditions and remaining valid until the April 15, 2036 expiration date.

What is the vesting schedule for Glenn Gormley’s Aktis Oncology (AKTS) option grant?

One-third of the original 37,866 options will vest on April 15, 2027. The remaining two-thirds will vest in equal annual installments thereafter, provided Glenn Gormley maintains continuous service with Aktis Oncology through each applicable vesting date.

When do Glenn Gormley’s Aktis Oncology (AKTS) stock options expire?

The granted stock options are scheduled to expire on April 15, 2036. After this expiration date, any unexercised options will lapse, so potential value from the award depends on vesting, continued service, and the company’s share price before that time.